/
/
/

Skybiotech Healthcare Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---0%
---0%
-31%5%-41%
-26%-26%-26%-26%

Peer Comparison

Symbol
PAGEIND-A
KPRMILL-A
WELSPUNLIV-A
VTL-A
ARVIND-A
MANYAVAR-A
PGIL-A
ICIL-A
SWANCORP-A
GARFIBRES-A
SKYBIOTECH-X
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
36,641.3₹41064 Cr54.33172.86775.02₹764 Cr
1,123.35₹37165 Cr40.747.5633.09₹867 Cr
229.55₹21356 Cr76.931.77.24₹204 Cr
533.15₹15077 Cr17.7810.745.91₹745 Cr
531.4₹13967 Cr33.722.0426.78₹414 Cr
513.2₹12295 Cr31.863.3222.96₹376 Cr
1,307.05₹11859 Cr38.2110.8843.68₹278 Cr
465₹8877 Cr58.833.1916.03₹127 Cr
275.2₹8340 Cr37.3-111.1₹274 Cr
764₹7482 Cr35.626.6225.24₹199 Cr
118.15₹23 Cr—-3-6.31-₹1 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
₹49 L₹2 Cr₹96 L₹2 Cr₹2 Cr₹1 Cr₹3 Cr₹2 Cr₹0₹0
₹6 L₹15 L₹8 L₹4 L₹4 L-₹18 L₹15 L₹4 L₹35 L₹60 L
₹55 L₹2 Cr₹1 Cr₹2 Cr₹2 Cr₹84 L₹3 Cr₹2 Cr₹35 L₹60 L
₹1 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹2 Cr₹4 L₹2 L
-₹46 L-₹73 L-₹36 L-₹19 L₹11 L-₹1 Cr-₹16 L₹7 L₹31 L₹58 L
₹40,000₹50,000₹40,000₹50,000₹70,000-₹23 L₹11 L₹14 L₹0₹0
-₹57 L-₹85 L-₹49 L-₹31 L-₹2 L-₹1 Cr-₹41 L-₹19 L₹31 L₹58 L
-₹57 L-₹30 L-₹49 L-₹31 L-₹2 L-₹1 Cr-₹39 L-₹25 L₹25 L₹49 L

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025
—
₹2 Cr
₹7 Cr
₹7 Cr
₹9 Cr
₹2 Cr
₹7 Cr
-₹92 L
₹6 Cr
—
₹62 L
₹1 Cr
₹19 L
₹74 L
₹3 Cr
₹19 Cr
₹7 Cr
—
₹21 Cr
₹9 Cr
₹12 Cr
₹2 Cr
₹2 Cr
₹3 Cr
₹15,000
₹17 Cr
—
₹2 Cr
₹42 L
-₹27 L
₹14,000
₹17 L
₹2 Cr
-₹64 L
₹19 Cr
₹47
₹47

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2025
-₹2 Cr
-₹9 L
₹1 Cr
-₹1 Cr
-₹1 Cr
-₹10 Cr
₹1 Cr
-₹9 Cr
₹9 Cr
-₹27 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)0.00
Volume (₹)0.00
High (₹)0.00
Upper Circuit124.05
Low (₹)0.00
Lower Circuit112.25
Prev Close118.15
52W High (₹)218.20
Price118.15
52W Low (₹)113.90

Share Market Cap & Key Ratios Overview

M.Cap (₹)22.63 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.80
Price to Book3.49
Book Value46.93
EPS (TTM)-8.74
Face Value10.00
ROE (%)-26.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
PAGEIND-ANSE
KPRMILL-ANSE
WELSPUNLIV-ANSE
VTL-ANSE
ARVIND-ANSE
MANYAVAR-ANSE
PGIL-ANSE
ICIL-ANSE
SWANCORP-ANSE
GARFIBRES-ANSE
SKYBIOTECH-XNSE
LTP
1W Low
1W High
Market cap (₹)
36641.3-52.1 (-0.14%)
36345
36985
41,064Cr
1123.35+68.9 (6.53%)
1050
1125.75
37,165Cr
229.55+6.3 (2.82%)
220.30
234.25
21,356Cr
533.15+4.9 (0.93%)
513.40
539
15,077Cr
531.4+22.25 (4.37%)
498.95
532.30
13,967Cr
513.2+11.6 (2.31%)
490
516.35
12,295Cr
1307.05+26.9 (2.10%)
1220
1356.50
11,859Cr
465+28.5 (6.53%)
437.45
475.05
8,877Cr
275.2+14.25 (5.46%)
261.10
276.20
8,340Cr
764-1.05 (-0.14%)
761
787.65
7,482Cr
118.15+1.15 (0.98%)
117
118.15
23Cr

Skybiotech Healthcare Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹-₹46.4Lakh; with other income of ₹6.1Lakh, profit before interest and tax came to ₹-₹57Lakh. Interest expense was ₹40000 cr; PBT before exceptional items stood at ₹-₹57.4Lakh. Cost mix (full year): raw materials ₹3.67Cr; employee cost ₹1.96Cr; depreciation ₹10.6Lakh; other expenses ₹1.02Cr. Basis: consolidated annual results.

Skybiotech Healthcare Ltd Quaterly Results Key Takeaways

Skybiotech Healthcare Ltd reported ₹49.3Lakh total income from operations in Jun 2026, softer than ₹1.83Cr in Mar 2026 but higher than ₹2.39Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹-₹46.4Lakh; with other income of ₹6.1Lakh, profit before interest and tax came to ₹-₹57Lakh. Interest expense was ₹40000 cr, taking profit before tax to ₹-₹57.4Lakh. After tax of ₹0 cr, profit after tax stood at ₹-₹57.4Lakh (vs ₹-₹30.4Lakh in Mar 2026 and ₹-₹1.8Lakh in Jun 2025).